首页> 美国卫生研究院文献>Cancers >Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours
【2h】

Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours

机译:过继性细胞疗法-利用抗原特异性T细胞靶向实体瘤

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In recent years, much research has been focused on the field of adoptive cell therapies (ACT) that use native or genetically modified T cells as therapeutic tools. Immunotherapy with T cells expressing chimeric antigen receptors (CARs) demonstrated great success in the treatment of haematologic malignancies, whereas adoptive transfer of autologous tumour infiltrating lymphocytes (TILs) proved to be highly effective in metastatic melanoma. These encouraging results initiated many studies where ACT was tested as a treatment for various solid tumours. In this review, we provide an overview of the challenges of T cell-based immunotherapies of solid tumours. We describe alternative approaches for choosing the most efficient T cells for cancer treatment in terms of their tumour-specificity and phenotype. Finally, we present strategies for improvement of anti-tumour potential of T cells, including combination therapies.
机译:近年来,许多研究都集中在使用天然或基因修饰的T细胞作为治疗工具的过继细胞治疗(ACT)领域。 T细胞表达嵌合抗原受体(CARs)的免疫疗法在血液系统恶性肿瘤的治疗中显示出巨大的成功,而自体肿瘤浸润淋巴细胞(TILs)的过继转移在转移性黑色素瘤中被证明是非常有效的。这些令人鼓舞的结果引发了许多研究,其中测试了ACT作为各种实体瘤的治疗方法。在这篇综述中,我们概述了基于T细胞的实体瘤免疫疗法所面临的挑战。我们根据肿瘤特异性和表型描述了选择最有效的T细胞进行癌症治疗的替代方法。最后,我们提出了改善T细胞抗肿瘤潜能的策略,包括联合疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号